See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Medicxi is a leading European life sciences venture capital firm with a mission to create and invest in companies across the full drug development continuum. The firm pioneered the 'asset-centric' investment model — backing biotechnology companies built around a single, highly validated drug asset with a clear product vision to fulfil an unmet medical need — rather than diversified platform companies. This capital-efficient approach concentrates diversification at the portfolio level, not within individual companies, enabling faster, leaner paths to clinical proof-of-concept and pharma partnership or acquisition. Medicxi invests in early- and late-stage therapeutics, both by creating new companies from scratch alongside drug hunters and entrepreneurs, and by investing in existing companies at all stages of development that align with its asset-centric value creation strategy.
Notable quotes
“Medicxi's longstanding success has been founded on its unique ties to leading global pharmaceutical companies and its world-class team of drug hunters and clinicians. The new €500 million fund will enable Medicxi to provide the critical capital, expertise and experience to deliver transformative therapies for patients.”
“Medicxi's differentiated, capital-efficient investment strategy is rapidly scaling and we have now raised six funds in the last 10 years, totalling over €2.0 billion. We are extremely grateful for the support that we have received from our existing and new limited partners, and we are excited to continue investing in cutting-edge science and accelerating the discovery of life-changing medicines for patients.”
“Our mission is to support the innovative genius of entrepreneurs by providing the critical capital, expertise and experience that form the all-important 'bridge' to pharma. This new fund consolidates Medicxi's position as a key operating platform for scientific entrepreneurs and drug hunters and is deliberately sized for our investment model.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Altesa BioSciences | Series B | $75m | 2026-02-19 |
| D3 Bio | Series B | $108m | 2025-12-10 |
| FORE Biotherapeutics | Series D | $38m | 2025-05-06 |
| Curevo Vaccine | Series B | $110m | 2024-01-01 |
| Centessa Pharmaceuticals | Series A | $250m | 2021-02-16 |
| Merus N.V. | Series B+ | — | — |
| Vaxcyte | Series B+ | — | — |
| Abivax | Series B+ | — | — |
| ViceBio | Seed | — | — |
| Aura Biosciences | Series B+ | — | — |
Frequent co-investors
| VC firm | Deals together |
|---|---|
| General Atlantic | 3 |
| Forbion | 3 |
| OrbiMed | 3 |
| Vida Ventures | 2 |
| Temasek | 2 |
| Cormorant Asset Management | 2 |
Fit check
Is Medicxi a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit